MedTrace Logo

Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)

NCT02273856 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2016-06-21

No results posted yet for this study

Summary

The purpose of this study is to document the pharmacological treatment strategies used in treatment naïve and previously treated relapsed/refractory iNHL/CLL patients in the Middle East and North African (MENA) region. This study will also record encountered tumor subtype and stage and the instituted pharmacological treatments, as well as assess the clinical outcomes of treatments.

Conditions

  • Indolent Non Hodgkin's Lymphoma (iNHL)
  • Chronic Lymphocytic Leukaemia (CLL)

Sponsors & Collaborators

  • Astellas Pharma International B.V.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma International B.V.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • Jordan
  • Kuwait
  • Lebanon
  • Oman
  • Qatar
  • Saudi Arabia
  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02273856 on ClinicalTrials.gov